Mupirocin Patent Expiration
Mupirocin was first introduced by Glaxosmithkline
Mupirocin Patents
Given below is the list of patents protecting Mupirocin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Centany | US6013657 | Pharmaceutical compositions containing mupirocin |
Jul 08, 2018
(Expired) | Padagis Us |
About Veterinary Mupirocin
Mupirocin is used in drugs marketed by 3 different companies: Taro Pharmaceuticals Usa Inc, Zoetis Inc, Fougera Pharmaceuticals Llc.
Other drugs containing Mupirocin are: Muricin , Mupirocin ointment usp, 2% , Bactoderm ointment .
Mupirocin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Mupirocin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment | Johns Hopkins University | NA |
RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Staph Nasal Decolonization to Improve Function and Feeding | David Palma | NA |
NOT YET RECRUITING
(Apr 1, 2026)
| PHASE2 |